Abstract
Cell-based tolerogenic therapy is a promising approach for the treatment of autoimmune diseases and transplant rejection. Regulatory T cells and tolerogenic dendritic cells have been particularly explored in the treatment of various autoimmune disorders in experimental models of disease. Although some of these cells have already been tested in a limited number of clinical trials, there is still a need for preclinical research on tolerogenic cells in animal models of autoimmunity. This review will focus on the relevance of data obtained from studies in experimental animal models for the use of tolerogenic cell-based therapy in humans. Also, perspectives for further improvement of tolerogenic cell preparation towards enhanced suppressive activity and stability of the cells will be discussed.
Keywords: Cell-based tolerogenic therapy, regulatory T cells, tolerogenic dendritic cells, multiple sclerosis, type 1 diabetes, rheumatoid arthritis.
Current Pharmaceutical Design
Title:Cell-based Tolerogenic Therapy, Experience from Animal Models of Multiple Sclerosis, Type 1 Diabetes and Rheumatoid Arthritis
Volume: 23 Issue: 18
Author(s): Ivana Stojanovic, Mirjana Dimitrijevic, Marta Vives-Pi, Maria Jose Mansilla, Irma Pujol-Autonell, Silvia Rodríguez-Fernandez, Lenka Palova-Jelínkova, David P. Funda, Alisa Gruden-Movsesijan, Ljiljana Sofronic-Milosavljevic, Catharien M. U. Hilkens, Eva Martinez Caceres and Djordje Miljkovic*
Affiliation:
- Institute for Biological Research "Sinisa Stankovic", Department of Immunology, Despota Stefana 142, 11000 Belgrade,Serbia
Keywords: Cell-based tolerogenic therapy, regulatory T cells, tolerogenic dendritic cells, multiple sclerosis, type 1 diabetes, rheumatoid arthritis.
Abstract: Cell-based tolerogenic therapy is a promising approach for the treatment of autoimmune diseases and transplant rejection. Regulatory T cells and tolerogenic dendritic cells have been particularly explored in the treatment of various autoimmune disorders in experimental models of disease. Although some of these cells have already been tested in a limited number of clinical trials, there is still a need for preclinical research on tolerogenic cells in animal models of autoimmunity. This review will focus on the relevance of data obtained from studies in experimental animal models for the use of tolerogenic cell-based therapy in humans. Also, perspectives for further improvement of tolerogenic cell preparation towards enhanced suppressive activity and stability of the cells will be discussed.
Export Options
About this article
Cite this article as:
Stojanovic Ivana, Dimitrijevic Mirjana, Vives-Pi Marta, Mansilla Jose Maria, Pujol-Autonell Irma, Rodríguez-Fernandez Silvia, Palova-Jelínkova Lenka, Funda P. David, Gruden-Movsesijan Alisa, Sofronic-Milosavljevic Ljiljana, Hilkens M. U. Catharien, Caceres Martinez Eva and Miljkovic Djordje*, Cell-based Tolerogenic Therapy, Experience from Animal Models of Multiple Sclerosis, Type 1 Diabetes and Rheumatoid Arthritis, Current Pharmaceutical Design 2017; 23 (18) . https://dx.doi.org/10.2174/1381612823666170214120708
DOI https://dx.doi.org/10.2174/1381612823666170214120708 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Curcumin, an Active Constiuent of the Ancient Medicinal Herb Curcuma longa L.: Some Uses and the Establishment and Biological Basis of Medical Efficacy
CNS & Neurological Disorders - Drug Targets Metallic Nanopopcorns: A New Multimodal Approach for Theranostics
Current Nanoscience The Use of Ghrelin and Ghrelin Receptor Agonists as a Treatment for Animal Models of Disease: Efficacy and Mechanism
Current Pharmaceutical Design Caveats Regarding the Use of IL-10 and IL-10 Antagonist as Immunotherapeutic Factors
Letters in Drug Design & Discovery New Use for Old Drugs? Prospective Targets of Chloroquines in Cancer Therapy
Current Drug Targets MMP Inhibitors in Cardiac Diseases: An Update
Recent Patents on Cardiovascular Drug Discovery Oxidative stress and myocarditis
Current Pharmaceutical Design Adenosine A<sub>3</sub> Receptor: A promising therapeutic target in cardiovascular disease
Current Cardiology Reviews Cyclooxygenases Regulation by Estradiol on Endothelium
Current Pharmaceutical Design Congenital Malformations Attributed to Prenatal Exposure to Cyclophosphamide
Anti-Cancer Agents in Medicinal Chemistry Peptides, Proteins and Peptide/Protein-Polymer Conjugates as Drug Delivery System
Protein & Peptide Letters Capillaroscopic Findings in Primary Fibromyalgia
Current Rheumatology Reviews The Role of Melatonin in Rheumatic Diseases
Infectious Disorders - Drug Targets Torsades de Pointes in Patients with Polymyalgia Rheumatica
Current Pharmaceutical Design Small Intestinal Injury Caused by NSAIDs/Aspirin: Finding New from Old
Current Medicinal Chemistry Cardiovascular Risk Factors in Chronic Inflammatory Rheumatic Diseases: Modern Assessment and Diagnosis
Current Vascular Pharmacology New Molecules as Drug Candidates for the Treatment of Upper and Lower GI Tract Ulcers
Current Pharmaceutical Design Pharmaceutical and Pharmacodynamic Evaluation of Naproxen Incorporated Aloe vera Transgel
Drug Delivery Letters Phytochemical and Biological Activities of five Turanecio Hamzaoglu (Asteraceae) Species from Turkey
Current Enzyme Inhibition Elaboration of New Anti-Inflammatory Agents Using Pharmacophore Based 3D QSAR of 4, 5-Diaryl Imidazoline as P2X7 Receptor Antagonists
Letters in Drug Design & Discovery